Market Overview:
The global preventive healthcare technologies and services market size is expected to exhibit a CAGR of 11.91% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Growth Rate (2024-2032) |
11.91% |
Preventive healthcare technologies and services refer to measures taken by healthcare providers to identify future illnesses and treatments. It includes early detection and screening, prophylaxis, chronic disease management, vaccines, and advanced technologies to reduce errors. Preventive healthcare technologies and services utilize various devices to measure daily health parameters, such as blood oxygen saturation, blood pressure, heart rate, and sleep patterns. This, in turn, assists healthcare professionals in screening, check-ups, and patient counseling to identify and prevent various health problems. As a result, they are extensively adopted in hospitals and clinics to eradicate, eliminate, and minimize the negative impact of various diseases.
Preventive Healthcare Technologies and Services Market Trends:
The rising geriatric population across the globe is creating a positive outlook for the market. Preventive healthcare technologies and services are widely adopted to prevent or identify problems at an early stage and decrease the risks of chronic illnesses, such as cardiovascular diseases (CVDs), diabetes, cancer, hypertension, respiratory ailments, and other contagious diseases. Furthermore, significant technological advancements in the healthcare system, coupled with the rising adoption of self-monitoring devices to increase awareness and reduce the cost burden, are acting as other growth-inducing factors. Additionally, the integration of artificial intelligence (AI) in healthcare technology to identify and predict diseases and provide personalized and accurate assumptions and treatment methods based on patients’ history is providing an impetus to the market growth. Moreover, the widespread adoption of cloud-based technologies to enhance operational efficiency, clinical quality, and delivery of preventive healthcare is further supporting market growth. Other factors, including the implementation of various government initiatives supporting vaccination programs to improve life expectancy, extensive research and development (R&D) activities, and increasing public awareness regarding preventive methods, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global preventive healthcare technologies and services market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type and application.
Breakup by Type:
- Early Detection and Screening
- Vaccines
- Chronic Diseases Management
- Advanced Technologies to Reduce Errors
Breakup by Application:
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Omron Healthcare Inc., Pfizer Inc., Quest Diagnostics and Sanofi S.A.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Type, Application, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Omron Healthcare Inc., Pfizer Inc., Quest Diagnostics and Sanofi S.A. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |